Literature DB >> 11571213

Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22.

S M Rosso1, W Kamphorst, B de Graaf, R Willemsen, R Ravid, M F Niermeijer, M G Spillantini, P Heutink, J C van Swieten.   

Abstract

Hereditary frontotemporal dementia (FTD) is an autosomal dominant neurodegenerative disorder that is associated with mutations in the tau gene and with the pathological accumulation of hyperphosphorylated tau protein in affected brain cells in about a quarter of cases. However, most FTD families have no demonstrable tau mutations. Here we describe the clinical and neuropathological features of a large family with hereditary FTD. Genetic analysis showed strong evidence for linkage to chromosome 17q21-22 (maximum lod score 3.46, theta = 0 for marker D17S950), but mutations in the tau gene were not found. Clinical symptoms, neuropsychological deficits and neuroimaging findings of affected family members were similar to sporadic and tau-related FTD. The mean age at onset was 61.2 years, with loss of initiative and decreased spontaneous speech as the most prominent presenting symptoms. Pathological examination of the brains of two affected family members showed non-specific neuronal degeneration with dense cytoplasmic ubiquitin-positive inclusions in neurones of the second layer of the frontotemporal cortex and dentate gyrus of the hippocampus. In a number of neurones these inclusions appeared to be located inside the nucleus, although due to the small number of these inclusions this localization could not be confirmed by electron microscopy. The inclusions were not stained by tau, alpha-synuclein or polyglutamine antibodies. Biochemical analysis of soluble tau did not reveal abnormalities in tau isoform distribution and analysis of mRNA showed the presence of both three- and four-repeat transcripts. This is the first report of ubiquitin-positive, tau-negative inclusions in an FTD family with significant linkage to chromosome 17q21-22. Further characterization of the ubiquitin-positive inclusions may clarify the neurodegenerative pathways involved in this subtype of FTD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571213     DOI: 10.1093/brain/124.10.1948

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  34 in total

1.  Absence of pathogenic mutations in presenilin homologue 2 in a conclusively 17-linked tau-negative dementia family.

Authors:  R Rademakers; M Van den Broeck; K Sleegers; C van Duijn; C Van Broeckhoven; M Cruts
Journal:  Neurogenetics       Date:  2003-10-08       Impact factor: 2.660

Review 2.  Young onset dementia.

Authors:  E L Sampson; J D Warren; M N Rossor
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401

3.  Global gene profiling of VCP-associated inclusion body myopathy.

Authors:  Angèle Nalbandian; Svetlana Ghimbovschi; Shlomit Radom-Aizik; Eric Dec; Jouni Vesa; Barbara Martin; Susan Knoblach; Charles Smith; Eric Hoffman; Virginia E Kimonis
Journal:  Clin Transl Sci       Date:  2012-04-04       Impact factor: 4.689

4.  Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies.

Authors:  Deepak M Sampathu; Manuela Neumann; Linda K Kwong; Thomas T Chou; Matthew Micsenyi; Adam Truax; Jennifer Bruce; Murray Grossman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

Review 5.  Frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

Review 6.  Frontotemporal lobar degeneration: current knowledge and future challenges.

Authors:  Chiara Cerami; Elio Scarpini; Stefano F Cappa; Daniela Galimberti
Journal:  J Neurol       Date:  2012-04-25       Impact factor: 4.849

7.  Prominent phenotypic variability associated with mutations in Progranulin.

Authors:  Brendan J Kelley; Wael Haidar; Bradley F Boeve; Matt Baker; Neill R Graff-Radford; Thomas Krefft; Andrew R Frank; Clifford R Jack; Maria Shiung; David S Knopman; Keith A Josephs; Sotirios A Parashos; Rosa Rademakers; Mike Hutton; Stuart Pickering-Brown; Jennifer Adamson; Karen M Kuntz; Dennis W Dickson; Joseph E Parisi; Glenn E Smith; Robert J Ivnik; Ronald C Petersen
Journal:  Neurobiol Aging       Date:  2007-10-18       Impact factor: 4.673

Review 8.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

Review 9.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

10.  Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation.

Authors:  Lena Skoglund; RoseMarie Brundin; Tommie Olofsson; Hannu Kalimo; Sofie Ingvast; Elin S Blom; Vilmantas Giedraitis; Martin Ingelsson; Lars Lannfelt; Hans Basun; Anna Glaser
Journal:  Neurogenetics       Date:  2008-10-15       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.